OrphanPacific Announces the Launch of Joenja^® (leniolisib) in Japan for the Treatment of APDS in Adults and Pediatric Patients 4 Years of Age and Older

Announcement of Launch in Japan of RAVICTI^® Oral Liquid 1.1 g/mL

OrphanPacific Obtains Marketing Approval in Japan for Leniolisib (Joenja^®) for the Treatment of APDS for adults and pediatric patients 4 years of age and older